| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Autoimmune Dementia Profile, CSF
MessageSendout, Mayo test code: DMC2
Test Code
LAB1238033
Alias/See Also
AMPA-R Ab CBA
Amphiphysin Ab
Anti-Glial Nuclear Ab, Type 1
Anti-Neuronal Nuclear Ab, Type 1
Anti-Neuronal Nuclear Ab, Type 2
Anti-Neuronal Nuclear Ab, Type 3
CASPR2-IgG
Cognitive decline
Cognitive impairment
Contactin-Associated Protein-Like-2 (CASPR2)-IgG
CRMP-5-IgG
DEMEC
DPPX
dipeptidyl aminopeptidase-like protein 6
GABA-B-R Ab CBA
Glutamic Acid Decarboxylase (GAD65)
LGI1-IgG
NMDA-R Ab CBA
metabotropic glutamate receptor 1
mGluR1
Purkinje Cell Cytoplasmic Ab Type 2
GFAP
IgLON5
NIF
Leucine-Rich Glioma Inactivated Protein-1 IgG
Purkinje Cell Cytoplasmic Ab Type Tr
Neurochondrin Antibody (NCDN-2)
Phosphodiesterase 10A (PDE10A)
Tripartite Motif-Containing Protein 46 (TRIM46)
Amphiphysin Ab
Anti-Glial Nuclear Ab, Type 1
Anti-Neuronal Nuclear Ab, Type 1
Anti-Neuronal Nuclear Ab, Type 2
Anti-Neuronal Nuclear Ab, Type 3
CASPR2-IgG
Cognitive decline
Cognitive impairment
Contactin-Associated Protein-Like-2 (CASPR2)-IgG
CRMP-5-IgG
DEMEC
DPPX
dipeptidyl aminopeptidase-like protein 6
GABA-B-R Ab CBA
Glutamic Acid Decarboxylase (GAD65)
LGI1-IgG
NMDA-R Ab CBA
metabotropic glutamate receptor 1
mGluR1
Purkinje Cell Cytoplasmic Ab Type 2
GFAP
IgLON5
NIF
Leucine-Rich Glioma Inactivated Protein-1 IgG
Purkinje Cell Cytoplasmic Ab Type Tr
Neurochondrin Antibody (NCDN-2)
Phosphodiesterase 10A (PDE10A)
Tripartite Motif-Containing Protein 46 (TRIM46)
CPT Codes
86255 x 21, 86341
Preferred Specimen
Collection vial #1. 4 mL CSF
Minimum Volume
2 mL
Other Acceptable Specimens
Any collection vial
Transport Container
Sterile vial
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated (preferred): 28 days
Ambient: 72 hours
Frozen: 28 days
Ambient: 72 hours
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis, gross lipemia, gross icterus
Methodology
Indirect immunofluorescence Assay (IFA), Cell Binding Assay (CBA), Immunoblot (IB), Western Blot (WB), Radioimmunoassay (RIA)
Setup Schedule
Monday through Sunday; Reflex tests: Varies
Report Available
8 to 12 days
Reference Range
Included with report
Clinical Significance
Investigating new onset dementia and cognitive impairment plus 1 or more of the following accompaniments using cerebrospinal fluid specimens:
-Rapid onset and progression
-Fluctuating course
-Psychiatric accompaniments (psychosis, hallucinations)
-Movement disorder (myoclonus, tremor, dyskinesias)
-Headache
-Autoimmune stigmata (personal history or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, poliosis [premature graying], myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus)
-Smoking history (20 or more pack-years) or other cancer risk factors
-History of cancer
-Inflammatory cerebrospinal fluid
-Neuroimaging findings atypical for degenerative etiology
-Rapid onset and progression
-Fluctuating course
-Psychiatric accompaniments (psychosis, hallucinations)
-Movement disorder (myoclonus, tremor, dyskinesias)
-Headache
-Autoimmune stigmata (personal history or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, poliosis [premature graying], myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus)
-Smoking history (20 or more pack-years) or other cancer risk factors
-History of cancer
-Inflammatory cerebrospinal fluid
-Neuroimaging findings atypical for degenerative etiology
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Dementia, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

